INTRODUCTION
The mammalian heart synthesizes and secretes atrial natriuretic peptide (ANP), a vasorelaxant factor displaying natriuretic and diuretic properties [1] . Although atrial stretch is generally considered to be the prime physiological stimulus inducing ANP release [2, 3] , little is known about the intracellular signalling mechanisms governing hormone-induced secretion of this peptide. Perfused heart, isolated atria and/or cultured cardiomyocytes secrete ANP upon stimulation with a number of vasoactive agents [4] [5] [6] [7] [8] , and it has been suggested that protein kinase C (PKC} activation, Ca2+ influx, cyclic AMP formation and/or endogenous prostaglandin production play important roles in this response [9] .
Numerous studies have shown the importance of angiotensin II (Ang II) in the regulation of blood pressure and the pathogenesis of hypertension [10] . In this respect, Ang II displays a multitude of cardiovascular effects, regulating intravascular volume and peripheral vascular resistance by increasing aldosterone production, renal Na+ reabsorption and arterial smoothmuscle cell contraction [11] . Not surprisingly, Ang II also exerts a direct effect on the heart, affecting cardiac contractility and promoting ANP release [6, 12, 13] , processes that are mediated by high-affinity myocardial Ang II receptors whose activation leads to both phospholipase C (PLC)-dependent phosphoinositide formation and Ca2+ mobilization in this tissue [14, 15] .
PKC is likely to play an important role in Ang Il-induced cardiac responses, as increases in PLC activity lead to the formation of PKC-activating diacylglycerols [16] . In agreement with this hypothesis, PKC activation is a major requirement for the induction of ANP secretion by the PLC-activating agents [9] .
PGF1a production was found to be strongly correlated with Ang Il-induced ANP release (r = 0.87, P < 0.001, n = 6), indicating a role for prostacycin (PGI2) in Ang Il-induced ANP secretion in these cells. This hypothesis was confirmed by finding that both Ang II-induced 6-oxo-PGF1I production and ANP release were abolished in the presence of the respective phospholipase A2 and cyclo-oxygenase inhibitors quinacrine (10 FM) and indomethacin (10 FM) , whereas exogenously applied PGI2 (1 FM) and prostaglandin E2 (0.1 FM) mimicked Ang Il-induced ANP secretion in this system. Taken together, these results suggest that Ang II induces ANP secretion in spontaneously beating rat cardiomyocytes via a PKC-dependent autocrine pathway involving a cyclo-oxygenase product and a yet-to-be-identified myocardial prostanoid receptor.
Interestingly, we have previously reported that the activation of PKC leads to increased prostacyclin (PGI2) and prostaglandin E2 (PGE2) production in spontaneously beating cultured cardiomyocytes [17] , whereas others have shown that cyclo-oxygenase inhibition abolishes ANP secretion induced by PLC-activating agonists in isolated atria [18] . Considering that prostaglandins are potent ANP secretagogues in their own right [19] , PKCmediated prostaglandin production may well be at the basis of Ang II-induced myocardial ANP secretion.
We investigated this hypothesis by stimulating spontaneously beating cultured neonatal-rat cardiomyocytes with Ang II and by measuring the effect in terms of PKC activation, 6-oxo-PGFla formation and ANP release both in the absence and presence of various PKC, phospholipase A2 (PLA2) and cyclo-oxygenase inhibitors, and in PKC-down-regulated cells. Results indicate that Ang Il-induced 6-oxo-PGF1. production and ANP secretion are PKC-mediated events, and that endogenous agonist-induced prostaglandin production is indeed at the basis of ANP release in this system. 
MATERIALS AND METHODS

Cell culture
Neonatal-rat ventricular cardiomyocytes were obtained from 1-2-day-old Wistar rats by a modification of the method of Kem et al. [20] . Briefly, the lower (apical) two-thirds of hearts were excised from decapitated rats and placed in 40 ml of icecold sterile HBSS containing 100 i.u./ml penicillin and 10 mg/ml streptomycin at 4 'C. The tissue was washed with 40 ml HBSS, cut into small pieces, further washed with 40 ml of HBSS and enzymically digested for 6 min with 10 ml of trypsin/DNAase (2.5 mg/ml and 0.3 mg/ml respectively) at 37 'C in a 50 ml sterile conical tube subjected to constant stirring. The supernatant from the first incubation was discarded, 10 ml of fresh enzyme solution was added, and the incubation procedure was repeated. Subsequent supernatants were collected and centrifuged at 200 g for 6 min and the resulting cell pellets were resuspended in HBSS containing 100% FCS at 37 'C. Once the sequential digestions were terminated, the cells were pooled, washed in 40 ml of McCoy's modified SA medium containing 10 % FCS, 1 % insulin/transferrin/sodium selenite medium supplement (ITS), 100 i.u./ml penicillin and 10 mg/ml streptomycin, and seeded in 90 mm plastic Petri dishes as described by Blondel et al. [21] . After 3 h of incubation, the Petri dishes were shaken and the supernatants containing the cardiomyocytes were pooled and seeded in 90 mm plastic Petri dishes or six-well culture plates (Costar, Cambridge, MA, U.S.A.). Most of the cultured cells (i.e. > 90%) began to contract spontaneously within 24-48 h of plating (30-60 beats/min) and exhibited positive staining for pro-ANP, the precursor form of rat ANP (Ile'2-oc-hANP; h = human) and a specific cardiomyocyte marker [1] . 6-Oxo-PGFia production co-purified with cellular ANP secretion when mesenchymal cells were eliminated from culture in accordance with Blondel et al. [21] , indicating that 6-oxo-PGF,a production originates from myoblasts and not from contaminating cell types. Substantiating this, cultured myocytes did not contain c-type PKC (rat fibroblast marker; see [17] and [22] ) or bind acetylated low-density lipoprotein (endothelial-cell marker; see [23] ). Confluent spontaneously beating cells were used on day 3 of culture for all experiments described herein.
Determination of PGI2 production and ANP release For assessment of PGI2 formation and ANP release, six-well tissue-culture plates containing confluent spontaneously contracting cardiomyocyte monolayers were washed with 2 ml of Krebs-Ringer buffer containing 0.2 % BSA and 0.2 % glucose as previously described [24] . After replacing the supernatant with 1 ml of fresh buffer, the cells were incubated at 37 'C for the indicated times in the presence of the various pharmacological agents, and 500 ,1 samples of the supernatants were collected and assayed for 6-oxo-PGF,, and ANP contents by radioimmunological methods previously described [25, 26] , omitting the semi-purification step required for assaying ANP levels in human plasma. The relative affinity of the anti-ANP antiserum for rat atriopeptides was as follows: a-hANP and rat ANP (Ile12-a-ANP), 100%; rat atriopeptin III, 100%; fl-hANP, 50%; yhANP, 40 %; rat atriopeptin II, 5 %; B-type natriuretic peptide (BNP), < 0.001 %; and both angiotensin II and atriopeptin I, 0 %. Cross-reactivity of the antiserum to 6-oxo-PGF1, has been previously studied in detail [25] .
Subcellular fractionation and determination of PKC activity Ang II-stimulated cells cultured in 90 mm plastic Petri dishes were subfractionated, and semi-purification of membrane and cytosolic PKC was carried out by DEAE-cellulose chromatography as described by Lang and Vallotton [27] . Eluates were assayed for PKC activity by measuring the incorporation of 32P from [y-32P]ATP into histone III-S in the absence and presence of lipid activators as previously indicated [25] . 
Statistical analysis
RESULTS
PKC mediates Ang l1-induced 6-oxo-PGF1a production and ANP release Incubation of spontaneously beating cultured rat cardiomyocytes with 0.1 ,tM Ang II led to a rapid increase in particulate-bound PKC activity (Figure 1 ). The response was transient, with maximal activation of PKC occurring at 5 min (+ 56 + 20.1 %; n = 3) and being followed by a rapid return to basal membrane PKC activity at 15 min. Overall, the transient increase in particulate-bound PKC activity was accompanied by a corresponding decrease in cytosolic PKC activity (-20.8 +4.20%, n = 4 at 5 min), indicating that Ang II induces the activation of cardiomyocyte PKC in a manner similar to, if not identical with, that previously reported for phorbol diesters in this preparation [17] . properties in both instances, the EC50s for Ang 1I-induced 6-oxo-PGF1. production and ANP release being estimated at 12 + 7.6 nM and 3 + 1.1 nM respectively (Figures 2b and 3b , n = 4).
As PKC activation is a potent signal for both cardiomyocyte prostaglandin formation and ANP secretion [9, 17] , we further investigated the role ofPKC in Ang II-induced cellular responses. As shown in Table 1 , incubation of cells with 0.1 ,uM Ang II in Table 1 Effect of PKC Inhibition on Ang Il-induced 6-oxo-PGF,,, production and ANP secretion Cultured cardiomyocytes were incubated with 0.1 ,#M Ang II for 1 h in the absence or presence of staurosporine (1 ,uM) or CGP 41251 (1 ,uM), and 6-oxo-PGFia production and ANP secretion were determined as described in the Materials and methods section. Results represent means + S.E.M. of n experiments (in parentheses) performed in triplicate determinations: *P < 0.05 versus control.
6-Oxo-PGF1. ( Table 1 ), suggesting that PKC activation accounts for a substantial portion of Ang 1I-induced PGI2 production and ANP release in this preparation.
Confirming this hypothesis, Ang 11-induced 6-oxo-PGF1a production and ANP release were severely decreased in cells pretreated with PMA (0.1 ,M), a widely used experimental method for the investigation of PKC-dependent processes [16] . Figure 4 , pretreatment of cells with 0.1,M PMA for 3 h led to the inhibition of both Ang II-induced 6-oxo-PGF1a production and ANP release (69 % and 88 % respectively), an inhibitory response nearly identical with that obtained with staurosporine and CGP 41521.
Endogenous prostaglandin production is at the basis of Ang Il-induced ANP secretion
The profile of Ang II-induced 6-oxo-PGF la production is similar to that obtained for Ang 1I-induced ANP release, suggesting that endogenous prostaglandin production is at the basis of ANP secretion in this system. Indeed, Ang II-induced 6-oxo-PGFia production was strongly correlated with cellular ANP release in experiments in which both variables were simultaneously tested (r = 0.87, P < 0.001, n = 6 at 15 min), whereas inhibition of both PLA2 and cyclo-oxygenase severely decreased Ang IIinduced ANP secretion in this preparation. As shown in Table 2 , the purported PLA2 inhibitor quinacrine (10 1M) decreased Ang IT-induced 6-oxo-PGFla production and ANP release by 61 % and 76 % respectively, an effect mimicked by the cyclo-oxygenase inhibitor indomethacin (10 M; 670% and 830% inhibition respectively). Table 2 Inhibition of Ang 1l-Induced 6-oxo-PGF1. production and ANP secretion by quinacrine and indomethacin Cultured cardiomyocytes were incubated with 0.1 ,uM Ang II for 1 h in the absence or presence of quinacrine (10 1sM) or indomethacin (10 ,M), and 6-oxo-PGF,, production and ANP secretion were determined as described in the Materials and methods section. Results represent means+ S.E.M. of n experiments (in parentheses) performed in triplicate determinations: *P < 0.05 versus control.
6-Oxo-PGF1. Spontaneously beating cultured cardiomyocytes simultaneously produce both PGI2 and PGE2 after PKC activation [17] . In this light, we finally incubated cells with both PGI2 and PGE2 and tested for enhanced ANP release. As shown in Table 3 (a), neither 1 ,uM ANP nor 0.5 mM 8-bromo cyclic GMP (a nonhydrolysable analogue of the intracellular effector of ANPreceptor activation; see [1] ) had an effect on cardiomyocyte 6-oxo-PGF1jformation. In contrast, incubation of cells with either 1 uM PGI2 or 0.1,IM PGE2 led to significant increases in ANP release (Table 3b) , responses confirming the hypothesis that endogenous prostaglandin production is at the basis of Ang IIinduced ANP release in this system.
DISCUSSION
Taken together, the present results strongly suggest that Ang IIinduced ANP secretion in spontaneously beating rat cardiomyocytes occurs via a PKC-dependent autocrine pathway involving a cyclo-oxygenase product and a yet-to-be-identified myocardial prostanoid receptor. This is supported by evidence that incubation of cardiomyocytes with Ang II simultaneously augments cellular 6-oxo-PGF1. formation, ANP release and membrane PKC activity, and that Ang II-induced ANP secretion is severely decreased in the presence of PKC, PLA2 and cyclooxygenase inhibitors, as well as in PKC-down-regulated cells.
Indeed, Ang II-induced 6-oxo-PGF1. production and ANP release exhibited strikingly similar kinetic profiles, and the EC50s for these responses are indistinguishable from the Kd for Ang IIbinding in rat myocardial tissue [14] . Finally, PGI2 and/or PGE2 appear to be the prostaglandin mediators underlying Ang IIinduced ANP release in this system, as both compounds induced an increase in ANP secretion in this preparation.
These results are consistent with the observation that PKC activation leads to rapid PGI2, PGE2 and ANP release in cultured rat cardiomyocytes [9, 17] and are also in agreement with the finding that cardiomyocytes contain angiotensin II receptors of the AT1 subtype [14] , the activation of which leads to PLCmediated phosphoinositide formation and PKC activation in this and/or in other systems [15, 27] . Indeed, PKC activation appears to be the principal signalling component underlying Ang II-induced responses in these cells, as phorbol diester pretreatment severely inhibited both Ang II-induced 6-oxo-PGF1, production and ANP release. In this context, it can be surmised that a certain amount of cytosolic PKC must be readily available in the basal (i.e. non-stimulated) state in order for Ang II to induce PKC translocation and subsequent prostaglandin-mediated ANP secretion, a conclusion in agreement with previous reports indicating that PKC activation is at the heart of ANP secretion induced by most PLCactivating agonists [9] .
Nevertheless, the exact nature of the cyclo-oxygenase metabolite mediating Ang II-induced ANP release remains to be fully elucidated. The concentration of exogenous PGI2 required for inducing ANP secretion was approx. 1000-fold higher than the amount of 6-oxo-PGF1. released by cardiomyocytes after stimulation with Ang II, suggesting that PGE2 is a more likely candidate for prostaglandin-mediated Ang II-induced ANP release. In agreement with this, nanomolar concentrations of PGE2 suffice in promoting ANP secretion in cultured cardiomyocytes (EC50 = 32 + 5 nM, n = 4; D. J. Church, unpublished work) and it has previously been shown that PKC activation leads to substantial PGE2 synthesis in these same cultures [17] .
Alternatively, the discrepancy between 6-oxo-PGF1a and PGI2 hydrophobicity, and/or by the fact that 6-oxo-PGF1, may [29] . In this respect, our results constitute the first report indicating that Ang II-induced ANP secretion occurs via the direct activation of spontaneously beating cardiomyocytes, a conclusion reinforcing the hypothesis that elevations of plasma renin, and subsequently Ang II, are directly responsible for the elevation of plasma ANP observed in models of heart failure [30] . Interestingly, ANP has been shown to inhibit both aldosterone secretion and renin release [31, 32] , illustrating a subtle retro-control of the mechanism of Ang IIinduced ANP secretion at the physiological level.
Finally, ANP has been shown to inhibit PKC-mediated responses in a variety of systems, a property carried out via the activation of cellular ANP receptors possessing guanylate cyclase properties [1] . In this light, the lack of effect of both ANP and 8-bromo cyclic GMP on cellular 6-oxo-PGF1, formation is consistent with the view that ANP exerts a negative feedback inhibition on cardiac tissue [33] and thus does not contribute to Ang II-induced cardiomyocyte stimulation. Conversely, both PGI2 and PGE2 are noted for their myocardium-stimulating effects, a property carried out through the receptor-mediated activation of adenylate cyclase [34] , an event leading to increases in both cellular contraction frequency and Ca2+ influx in this tissue [35, 36] . Interestingly, it has been shown that Ang IIinduces similar chronotropic and Ca2+-influx-activating effects in cultured neonatal cardiomyocytes [12] , suggesting that PKCdependent prostaglandin formation is also at the basis of Ang IIinduced changes in cardiomyocyte contractility, a hypothesis indirectly confirmed by the observation that phorbol diesters mimic Ang II-induced chronotropic responses in cultured myocytes [37] , whereas PMA induces a cyclo-oxygenase-product dependent increase in cyclic AMP formation in similar preparations [38] .
